|
|
||||||||
a Lung and Airway Laboratory, Federal University of Rio Grande do Sul School of Medicine, Hospital de Clínicas de Porto Alegre, Brazil
b Department of Anesthesiology, Federal University of Rio Grande do Sul School of Medicine, Hospital de Clínicas de Porto Alegre, Brazil
c Department of Pathology, Federal University of Rio Grande do Sul School of Medicine, Hospital de Clínicas de Porto Alegre, Brazil
d Gene Therapy Center, Federal University of Rio Grande do Sul School of Medicine, Hospital de Clínicas de Porto Alegre, Brazil
Received 19 August 2007; received in revised form 18 December 2007; accepted 19 December 2007.
* Corresponding author. Address: Hospital de Clínicas de Porto Alegre, Serviço de Cirurgia Torácica, Rua Ramiro Barcelos 2350, Sala 2050-M1, 90035-003 Porto Alegre, RS, Brazil. Tel.: +55 51 2101 8684; fax: +55 51 2101 8684. (Email: msaueressig{at}hcpa.ufrgs.br).
Objective: To evaluate the usefulness of gene therapy with human vascular endothelial growth factor 165 (phVEGF165) to promote the early re-establishment of systemic arterial perfusion in canine bronchi deprived of bronchial circulation. Methods: To disrupt bronchial circulation, dogs were submitted to transversal bronchotomy dividing the left mainstem bronchus into a proximal and a distal portion. phVEGF165 (VEGF group, n = 8) or physiologic saline solution (control group, n = 8) were then delivered to the left distal bronchus. After that, the airway was reconstituted with interrupted suture. On day 3, nine dogs (four VEGF and five controls) were euthanized and their left distal bronchi were harvested to evaluate VEGF165 gene expression by reverse transcription-polymerase chain reaction. In the other dogs (four VEGF and three controls), a microvascular dye was injected through the canine aorta to verify the re-establishment of arterial blood supply to the distal bronchus. Additionally, VEGF immunohistochemistry was performed in distal airway specimens. Results: Microvascular dye was observed in 100% of specimens transfected with phVEGF165 compared to none in controls. VEGF gene expression (p < 0.01) and VEGF protein expression (p < 0.05) were higher in VEGF165-treated bronchi. Conclusions: Local transfection with phVEGF165 promoted the early re-establishment of systemic arterial perfusion to bronchi previously deprived of bronchial circulation. Gene therapy with phVEGF165 may be a useful tool to restore bronchial circulation by promoting early airway angiogenesis.
Abbreviations: VEGF = vascular endothelial growth factor DNA = deoxyribonucleic acid phVEGF165 = naked plasmid enclosed human VEGF165 cDNA = complementary DNA bp = base pairs mRNA = messenger ribonucleic acid RT-PCR = reverse transcription-polymerase chain reaction GAPDH = glyceraldehydes-3-phosphate dehydrogenase RU = relative optical density unit PBS = phosphate-buffered saline
Key Words: Gene therapy Angiogenesis-inducing agents Pulmonary surgical procedures Models Animal Vascular endothelial growth factor
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |